Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medpace Holdings (MEX:MEDP) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Medpace Holdings Forward PE Ratio Related Terms
Medpace Holdings Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Medpace Holdings's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medpace Holdings Forward PE Ratio Chart
Medpace Holdings Annual Data
Trend
2020-12
2021-12
2022-12
2023-12
2024-12
2025-12
Forward PE Ratio
34.48
44.25
27.40
28.90
28.03
19.93
Medpace Holdings Quarterly Data
2019-03
2019-06
2019-09
2020-03
2020-06
2020-09
2020-12
2021-03
2021-06
2021-09
2021-12
2022-09
2022-12
2023-03
2023-06
2023-09
2023-12
2024-03
2024-06
2024-09
2024-12
2025-03
2025-06
2025-09
2025-12
2026-03
2026-06
Forward PE Ratio
19.65
20.83
24.27
20.96
39.06
23.09
34.48
37.59
41.49
36.50
44.25
24.39
27.40
30.03
26.46
25.00
28.90
26.53
33.11
26.67
28.03
26.89
24.52
20.72
19.93
19.22
23.67
MEX:MEDP vs ICLR, RVTY, CRL: Forward PE Ratio Comparison
For the Diagnostics & Research subindustry, Medpace Holdings's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medpace Holdings Forward PE Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Medpace Holdings's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Medpace Holdings (MEX:MEDP) has a Forward PE Ratio of 23.63 as of Jul. 25, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Medpace Holdings and its competitors. According to the industry distribution chart, Medpace Holdings ranks #63 out of 87 companies in the Medical Diagnostics & Research industry, placing it in the top 72.4%.
Is Medpace Holdings' Forward PE Ratio too high?
Medpace Holdings' current Forward PE Ratio is 23.63. The Medical Diagnostics & Research industry median Forward PE Ratio is 22.50. Medpace Holdings' value of 23.63 is 5% above this industry median. Based on the distribution chart, Medpace Holdings ranks #63 out of 87 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Medpace Holdings has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does Medpace Holdings' Forward PE Ratio compare to ICLR and RVTY?
According to the Medical Diagnostics & Research industry distribution chart, Medpace Holdings ranks #63 out of 87 companies for Forward PE Ratio. This places Medpace Holdings in the lower half of its industry. The industry median Forward PE Ratio is 22.50. Medpace Holdings' value of 23.63 is 5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Diagnostics & Research company?
The median Forward PE Ratio among Medical Diagnostics & Research companies is 22.50, based on 87 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medpace Holdings's current Forward PE Ratio of 23.63 is 5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Medpace Holdings and its competitors. For the Medical Diagnostics & Research industry, the median Forward PE Ratio is 22.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medpace Holdings's current Forward PE Ratio is 23.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medpace Holdings stock overvalued right now?
Medpace Holdings (MEX:MEDP) has a current Forward PE Ratio of 23.63. The stock's GF Value™ is MXN6,131.53, compared to a current price of MXN7,022.03 — trading 14.5% above its estimated fair value. The current Forward PE Ratio is 23.63 and 5% above the Medical Diagnostics & Research industry median of 22.50. Medpace Holdings' overall GF Score™ is 95/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Medpace Holdings (MEX:MEDP), the current Forward PE Ratio is 23.63 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medpace Holdings (MEX:MEDP) Overvalued in 2026?
Based on GuruFocus' analysis, Medpace Holdings stock appears to be overvalued.
The current stock price of MXN7,022.03 is trading 14.5% above its estimated GF Value™ of MXN6,131.53.
Key valuation signals for MEX:MEDP:
Forward PE Ratio: 23.63
GF Value™: MXN6,131.53 vs. price of MXN7,022.03 (14.5% above fair value)
Industry Position: 5% above the Medical Diagnostics & Research median (#63 of 87)
No single metric tells the full story. See the MEX:MEDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
95GF Score
Get the complete analysis for MEX:MEDP
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:MEDP has been successfully added to your 
